[1] ALEX J KROTULSKI. Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework.[J]. Journal of analytical toxicology, 2020, 44 6: 521-530. DOI:
10.1093/jat/bkaa016[2] MARTHE M. VANDEPUTTE. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids.[J]. ACS Chemical Neuroscience, 2021. DOI:
10.22541/au.160520665.59016513/v2[3] LAURA B KOZELL. Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity.[J]. Journal of Pharmacology and Experimental Therapeutics, 2024: 219-228. DOI:
10.1124/jpet.123.002052[4] OMAYEMA TAOUSSI. Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene[J]. Archives of Toxicology, 2024, 98 7: 2101-2116. DOI:
10.1007/s00204-024-03735-0[5] MENG-HUA M. TSAI, LEI SHI* In Vitro Functional Profiling of Fentanyl and Nitazene Analogs at the μ-Opioid Receptor Reveals High Efficacy for Gi Protein Signaling[J]. ACS Chemical Neuroscience, 2024, 15 4: 854-867. DOI:
10.1021/acschemneuro.3c00750[6] GRANT C GLATFELTER. Alkoxy chain length governs the potency of 2-benzylbenzimidazole “nitazene” opioids associated with human overdose.[J]. Psychopharmacology, 2023: 2573-2584. DOI:
10.1007/s00213-023-06451-2[7] NICHOLAS J MALCOLM. Mu-opioid receptor selective superagonists produce prolonged respiratory depression.[J]. iScience, 2023, 26 7: 107121. DOI:
10.1016/j.isci.2023.107121